Online evaluation for Zepbound (tirzepatide) for chronic weight management
Zepbound is FDA-approved for adults with obesity, or overweight plus a weight-related condition, used alongside reduced calories and more activity. Tirzepatide for weight loss acts on two receptors instead of one, which is why patients in trials lost more on it than on semaglutide. In trials, it produced clinically meaningful weight loss when used as directed.
FDA-approved
FDA-approved for chronic weight management in eligible adults, used alongside a reduced-calorie nutrition plan and more physical activity.
Multiple hunger pathways
Tirzepatide acts on two receptors, GLP-1 and GIP, that regulate appetite and how full you feel after meals. It also slows how fast your stomach empties. Your dose starts low and steps up over your first 4 months so your body can adapt.
Clinical results
In the 72-week SURMOUNT-1 trial, participants without diabetes lost an average of 16% to 22.5% of their body weight, depending on dose. The greatest loss was at 15mg, paired with diet and exercise.
Metabolic outcomes
In a long-term trial of adults with prediabetes and overweight or obesity, tirzepatide reduced progression to type 2 diabetes by 94% (relative risk reduction) versus placebo. Absolute risk reduction and individual outcomes vary based on baseline risk and adherence.
Based on your provider's likely recommendation and trial averages for that protocol after one year.
Starting weight: 260 lbs
You could lose:
52 pounds
Zepbound (tirzepatide) is an FDA-approved, once-weekly injection for chronic weight management in eligible adults with obesity, or overweight with at least one weight-related condition, used alongside a reduced-calorie nutrition plan and more physical activity. Its active ingredient is tirzepatide, which acts on two receptor pathways, GLP-1 and GIP, that regulate appetite and metabolism.
Medication name: Zepbound (tirzepatide)
Active ingredient: Tirzepatide
Drug type: GLP-1 + GIP receptor agonist
How it's taken: Once-weekly injection using a Zepbound KwikPen
Your Zepbound weight loss treatment is prescribed and monitored by a licensed Regenics provider. They decide whether tirzepatide is right for you, set your starting dose, and adjust it as you respond. Care is month-to-month. You message your provider anytime, and dose changes don't trigger a visit fee.
Your provider decides whether you qualify. Not an automated approval
Care is built around long-term weight management, not one-time prescribing
Your dose starts low and steps up based on how you respond and how you tolerate it
Tarzana clinic and telehealth both available
Follow-up appointments track side effects and how you're responding
Your care is managed by the same licensed Regenics providers throughout your treatment. Unlike platforms where patients may see a different provider each time, Regenics is designed to provide continuity of care. They get to know your health history, monitor your progress, adjust your treatment when needed, and provide personalized care every step of the way.
Philip Marks, MSN, FNP-C
Philip is a board-certified family nurse practitioner with more than 14 years of clinical experience. He earned his MSN from UCLA and a Post-Master's FNP-C from UC Irvine. At Regenics, he specializes in hormone optimization, weight management, and peptide and regenerative therapies.
Paula Barash, FNP-C
Paula Barash, is a board-certified family nurse practitioner with over 6 years of nursing experience. She earned her Master of Science in Nursing from West Coast University, with a clinical background in perioperative and surgical care. At Regenics, she focuses on weight management, hormone optimization, and medical aesthetics.
Joanna Stuppler, MSN, NP-C
Joanna Stuppler, is a board-certified nurse practitioner with over 10 years of clinical experience spanning critical care, transplant surgery, internal medicine, and weight loss. She earned her Master of Science in Nursing from the University of Texas at Arlington. At Regenics, she focuses on weight management and preventive care.
Anna Gryunshpan, FNP
Anna is a family nurse practitioner with over 9 years of experience in aesthetic medicine. At Regenics, she specializes in injectables, skin rejuvenation, body contouring, weight management, hormone optimization, and peptide therapy. She also serves as a nurse educator to RNs, NPs, and PAs.
Online consultation for tirzepatide
Start with a short health questionnaire. A licensed Regenics provider reviews your answers and decides whether tirzepatide is right for you, checking BMI, weight-related conditions, treatment history, and safety.
A provider reviews and prescribes
If you qualify, your Regenics provider builds a care plan with a starting dose and a schedule for stepping it up. The plan covers when you inject and when your dose increases. Your provider adjusts the dose based on how you respond and how you tolerate it.
Ongoing monitoring and follow-up support
Care continues month-to-month. Follow-up appointments let your provider review side effects and adjust your dose when needed. If your provider recommends anything beyond your monthly plan, you'll see the timing and any fees before you decide.
If Zepbound isn't the right fit, your Regenics provider can discuss other GLP-1 weight loss medications, including compounded semaglutide or brand-name, FDA approved Wegovy. What your provider recommends is based on your medical history and your goals.
Compounded · once-weekly injection
A good starting point if your provider wants to begin conservative or you're sensitive to GI side effects.
Brand-name · FDA-approved
Costs more than the compounded options, with FDA approval tied to that exact formulation.
These are individual patient experiences, not typical results. Individual results vary.
¹ Clinical trial data: In the 72-week SURMOUNT-1 study, participants receiving tirzepatide in combination with diet and exercise achieved mean weight reductions ranging from approximately 16% to 22.5%, depending on dose, with the highest reductions observed at 15 mg. Individual results vary.
² Long-term outcomes: In a 176-week clinical trial in adults with prediabetes and overweight or obesity, tirzepatide treatment was associated with a 94% relative reduction in progression to type 2 diabetes compared with placebo. Relative risk reduction differs from absolute risk reduction. Individual results vary.
³ Pricing: Pricing shown reflects the prescription-only monthly subscription. Medication cost is separate and paid through the pharmacy. Pricing may vary by clinical eligibility.
